Researchers evaluated the benefit-risk ratio across 3 ponatinib starting doses in patients with chronic phase chronic myeloid leukemia.
Dasatinib produced responses regardless of comorbidity burden.
Researchers sought to determine the risk of hepatotoxicity for patients with CML treated with 4 newer TKIs compared with imitanib.
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
An analysis of a registry of patients with CML and Philadelphia chromosome-positive ALL demonstrated that ponatinib is efficacious in those with relapsed or refractory disease.
A dose-reduction strategy in patients with CP-CML receiving dasatinib was shown to be feasible and may reduce adverse effects in these patients.
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
Patient advocate Marlena Murphy provides a patient’s perspective on GRASP.
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
The mortality rate was 0.13% in the overall chronic myeloid leukemia cohort.
A 45-mg starting dose, reduced to 15 mg, produced the best outcome.
Chronic myeloid leukemia (CML) can be painful and life-threatening if it is not caught in time. How can you educate patients with symptoms or who are newly diagnosed about the detection, symptoms, risk factors, and treatment of CML?
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
Researchers sought to determine the effects of fasting on drug absorption and efficacy in patients receiving TKIs for chronic myeloid leukemia.
Researchers sought to determine whether dasatinib and nilotinib would be effective second-line therapies for patients with chronic phase CML.
Researchers sought to determine key determinants of sustained treatment-free remission in patients with CML who have completed TKI treatment in an attempt to develop strategies that achieve long-term remission.
A case study with a literature review demonstrates potential antiviral effect of TKI therapy in patients with cancer and COVID-19.
Results of the ongoing OPTkIMA study comparing a fixed and a progressive TKI plan in patients with CML is discussed.
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.